Using retinol with minoxidil may not be as effective as tretinoin, but retinaldehyde or adapalene could be alternatives. A micro-roller with minoxidil is suggested for better results.
The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.
The user is allergic to minoxidil and experienced severe itching and redness. They are considering alternatives like finasteride, dutasteride, and dermarolling for hair loss treatment.
RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.
The user cannot tolerate oral finasteride and is considering topical finasteride, minoxidil, microneedling, and RU58841 as alternative treatments for hair loss. They seek advice on whether these options are worth trying.
The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.
The user plans to lower their oral minoxidil dose from 5 mg to 2.5 mg to reduce side effects like puffiness and hypertrichosis, while also using finasteride and accutane. They are considering caffeine serums for puffiness and discussing dietary changes or switching to topical minoxidil to address bloating.
The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
Investing in pharmaceutical products to treat hair loss and the potential risks associated with that, as well as other treatments such as Minoxidil, Finasteride, RU58841, and a COVID-19 booster.
Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
A user is starting treatment for hair loss with topical minoxidil, oral finasteride, and is considering adding topical latanoprost but is unsure about the application frequency and method for latanoprost. They are seeking advice from others with experience using these treatments.
Mixing minoxidil and alfatradiol in one bottle may affect their effectiveness due to potential stability issues. It's recommended to apply them separately for full benefits.
The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.
The conversation is about purchasing dutasteride solution for mesotherapy, with a suggestion to make it using dutasteride capsules and oils. A user shared a link to a potential supplier and mentioned using dutasteride with microneedling.
Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.
The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.
Oral minoxidil can cause side effects like shortness of breath and constipation, which may be reduced by taking it in the morning. Some users experience no side effects, while others switch to topical treatments or adjust their dosage and timing to manage symptoms.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.
A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.
User asked dermatologist for finasteride, received latanoprost and diprogenta cream instead. Others suggest latanoprost is expensive and not better than minoxidil, recommend trying another doctor for finasteride.
The conversation discusses using oral Minoxidil, a vasodilator, for both Raynaud's Syndrome and hair loss. It also inquires about other hair loss treatments that improve blood flow.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.